Clinical Trials

In what may have been one of the last advanced therapy meetings to go ahead for some time, delegates met in London in late February for CAR-TCR.

We catch up with a new CEO about his goals for a clinical trials business.

Why are compounds still failing at the final hurdle?

What challenges do manufacturers face in developing ADCs?

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.

A cell-free biologic could act as platform therapeutic for a variety of serious diseases.

Keeping the patient in mind is crucial for clinical research.

Can open source by applied to pharma R&D? This is the aim of Molecule.

"Biogen revitalizes hope for Alzheimer’s therapy, but their work highlights why we still need greater selectivity."

Male animal bias in preclinical research isn’t scientifically justified and may be skewing our understanding of the brain.